Literature DB >> 11161817

Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q).

F Lai1, L A Godley, J Joslin, A A Fernald, J Liu, R Espinosa, N Zhao, L Pamintuan, B G Till, R A Larson, Z Qian, M M Le Beau.   

Abstract

Loss of a whole chromosome 5, or a del(5q), are recurring abnormalities in malignant myeloid diseases. In previous studies, we defined a commonly deleted segment (CDS) of 1.5 Mb between D5S479 and D5S500 in patients with a del(5q), and we established a P1 artificial chromosome-based contig encompassing this interval. To identify candidate tumor suppressor genes (TSGs), we developed a transcript map of the CDS. The map contains 18 genes and 12 expressed sequence tags/UniGenes. Among the 18 genes are 10 genes that were previously cloned and 8 novel genes. The newly identified genes include CDC23, which encodes a component of the anaphase-promoting complex; RAB6KIFL, which encodes a kinesin-like protein involved in organelle transport; and KLHL3, which encodes a human homologue of the Drosophila ring canal protein, kelch. We determined the intron/exon organization of 14 genes and eliminated each gene as a classical TSG by mutation analysis. In addition, we established a single-nucleotide polymorphism map as well as a map of the mouse genome that is syntenic to the CDS of human 5q31. The development of a transcription map will facilitate the molecular cloning of a myeloid leukemia suppressor gene on 5q. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161817     DOI: 10.1006/geno.2000.6414

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  30 in total

Review 1.  Molecular dissection of the 5q deletion in myelodysplastic syndrome.

Authors:  Benjamin L Ebert
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

2.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

Review 3.  Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.

Authors:  H Sill; W Olipitz; A Zebisch; E Schulz; A Wölfler
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 4.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

5.  Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.

Authors:  Andres Jerez; Lukasz P Gondek; Anna M Jankowska; Hideki Makishima; Bartlomiej Przychodzen; Ramon V Tiu; Christine L O'Keefe; Azim M Mohamedali; Denise Batista; Mikkael A Sekeres; Michael A McDevitt; Ghulam J Mufti; Jaroslaw P Maciejewski
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

6.  Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice.

Authors:  Tim H-P Chen; Amal Kambal; Kilannin Krysiak; Mark A Walshauser; Gagan Raju; Justin F Tibbitts; Matthew J Walter
Journal:  Blood       Date:  2010-12-01       Impact factor: 22.113

Review 7.  Myelodysplastic syndromes.

Authors:  Olatoyosi Odenike; John Anastasi; Michelle M Le Beau
Journal:  Clin Lab Med       Date:  2011-10-10       Impact factor: 1.935

Review 8.  Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia.

Authors:  Zhijian Qian; John M Joslin; Thelma R Tennant; Shalini C Reshmi; David J Young; Angela Stoddart; Richard A Larson; Michelle M Le Beau
Journal:  Chem Biol Interact       Date:  2009-12-01       Impact factor: 5.192

9.  Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis.

Authors:  Timothy A Graubert; Michelle A Payton; Jin Shao; Richard A Walgren; Ryan S Monahan; John L Frater; Mark A Walshauser; Mike G Martin; Yumi Kasai; Matthew J Walter
Journal:  PLoS One       Date:  2009-02-25       Impact factor: 3.240

10.  A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.

Authors:  Jillian L Barlow; Lesley F Drynan; Duncan R Hewett; Luke R Holmes; Silvia Lorenzo-Abalde; Alison L Lane; Helen E Jolin; Richard Pannell; Angela J Middleton; See Heng Wong; Alan J Warren; James S Wainscoat; Jacqueline Boultwood; Andrew N J McKenzie
Journal:  Nat Med       Date:  2009-11-22       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.